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an analysis of data from a four-decade longitudinal study
Daniel W Belsky, Malcolm R Sears, Robert J Hancox, HonaLee Harrington, Renate Houts, Terrie E Moﬃ  tt, Karen Sugden, Benjamin Williams, 
Richie Poulton, Avshalom Caspi
Summary
Background Genome-wide association studies (GWAS) have discovered genetic variants that predispose individuals to 
asthma. To integrate these new discoveries with emerging models of asthma pathobiology, we aimed to test how 
genetic discoveries relate to developmental and biological characteristics of asthma. 
Methods In this prospective longitudinal study, we investigated a multilocus proﬁ le of genetic risk derived from 
published GWAS of asthma case status. We then tested associations between this genetic risk score and 
developmental and biological characteristics of asthma in participants enrolled in a population-based long-running 
birth cohort, the Dunedin Multidisciplinary Health and Development Study (n=1037). We used data on asthma 
onset, asthma persistence, atopy, airway hyper-responsiveness, incompletely reversible airﬂ ow obstruction, and 
asthma-related school and work absenteeism and hospital admissions obtained during nine prospective assessments 
spanning the ages of 9 to 38 years. Analyses included cohort members of European descent from whom genetic data 
had been obtained.
Findings Of the 880 cohort members included in our analysis, those at higher genetic risk developed asthma earlier in 
life than did those with lower genetic risk (hazard ratio [HR] 1·12, 95% CI 1·01–1·26). Of cohort members with 
childhood-onset asthma, those with higher genetic risk were more likely to develop life-course-persistent asthma than 
were those with a lower genetic risk (relative risk [RR] 1·36, 95% CI 1·14–1·63). Participants with asthma at higher 
genetic risk more often had atopy (RR 1·07, 1·01–1·14), airway hyper-responsiveness (RR 1·16, 1·03–1·32), and 
incompletely reversible airﬂ ow obstruction (RR 1·28, 1·04–1·57) than did those with a lower genetic risk. They were 
also more likely to miss school or work (incident rate ratio 1·38, 1·02–1·86) and be admitted to hospital (HR 1·38, 
1·07–1·79) because of asthma. Genotypic information about asthma risk was independent of and additive to information 
derived from cohort members’ family histories of asthma. 
Interpretation Our ﬁ ndings conﬁ rm that GWAS discoveries for asthma are associated with a childhood-onset 
phenotype. Genetic risk assessments might be able to predict which childhood-onset asthma cases remit and which 
become life-course-persistent, who might develop impaired lung function, and the burden of asthma in terms of 
missed school and work and hospital admissions, although these predictions are not suﬃ  ciently sensitive or speciﬁ c 
to support immediate clinical translation.
Funding US National Institute on Aging and UK Medical Research Council. 
Introduction
Asthma is a heterogeneous syndrome with several 
causes.1 Research is beginning to uncover variations in 
the molecular roots and clinical manifestations of 
asthma.2 One research stream has discovered molecular 
genetic markers of asthma risk.3,4 Another research 
stream has characterised developmental and biological 
features of asthma that might represent so-called 
endotypes—ie, subtypes of disease with distinct 
pathobiology.5,6 Bringing these two streams of research 
together could uncover how recently discovered genetic 
risks relate to developmental and biological characteristics 
of asthma. 
Our research seeks to address the question: when 
hypothesis-free methods such as genome-wide 
association studies (GWAS)7 make discoveries about 
heterogeneous syndromes such as asthma, what are 
these discoveries about? To achieve samples of tens of 
thousands, the largest asthma GWAS reduce this 
developmentally and biologically complex syndrome to 
a single outcome—for example, whether or not a 
physician has diagnosed asthma. Follow-up research is 
needed to fully understand discoveries from these 
studies. One approach is to work from the bottom up by 
tracing the path from variations in DNA sequences to 
diﬀ erences in RNA transcription, subsequent protein 
production, and onwards up through disease 
pathogenesis to identify a process or molecule that can 
be targeted for intervention. A complementary approach 
is to work from the top down by characterising how 
genetic discoveries relate to individual diﬀ erences in 
developmental and biological phenotypes, and then 
working backwards to devise interventions that can 
mitigate genetic risk.8 
We aimed to take the top-down approach to identify 
developmental and biological signatures of asthma in 
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individuals with high genetic risk. Once identiﬁ ed, these 
signatures can help to guide bottom-up molecular 
research. We aimed to construct a multilocus proﬁ le of 
genetic predisposition to asthma—a genetic risk score—
from a comprehensive case-control GWAS of asthma9 
and then to genotype this score in an unselected cohort 
followed up from birth to mid-life10 with extensive asthma 
phenotyping across nine assessments spanning the ages 
of 9–38 years. We then wanted to test how GWAS-
discovered genetic risks were related to the development, 
persistence, and biological characteristics of asthma in 
this cohort. 
Methods
Study design and participants
In this prospective longitudinal study, we used data 
from members of the Dunedin Multidisciplinary Health 
and Development Study, a longitudinal investigation of 
health and behaviour in a complete (unselected) birth 
cohort. Study members (1037; 91% of eligible births; 
52% male) were all individuals born between April, 
1972, and March, 1973, in Dunedin, New Zealand, who 
were eligible for the longitudinal study on the basis of 
residence in the province at age 3 years and who 
participated in the ﬁ rst follow-up assessment at age 
3 years. The cohort represents the full range of 
socioeconomic status in the general population of New 
Zealand’s South Island and is mainly white.11 
Assessments were done at birth and ages 3, 5, 7, 9, 11, 
13, 15, 18, 21, 26, 32, and, most recently, 38 years, when 
961 (95%) of the 1007 surviving study members took 
part. At each assessment wave, study members are 
brought to the Dunedin research unit for a full day of 
interviews and examinations. The Otago Ethics 
Committee approved each phase of the study and 
informed consent was obtained from all study members.
Procedures
To test whether genetic risk was associated with the 
timing of onset, course, and persistence of asthma, we 
analysed longitudinal data on asthma phenotypes derived 
from standardised interviews of Dunedin Study 
members. To test whether genetic risk was associated 
with asthma’s biological characteristics, we combined 
interview data with information derived from 
assessments of allergy and lung function. We examined 
three biological characteristics: atopy, which, especially 
in paediatric populations, is associated with a 
persistent and severe course of asthma;12,13 airway 
hyper-responsiveness, which provides indirect con-
ﬁ rmation of active airway inﬂ ammation;14,15 and 
incompletely reversible airﬂ ow obstruction, which 
identiﬁ es harmful changes to the airways resulting from 
chronic asthma.16 To accompany these aetiological 
analyses, we did two additional tests that related to the 
concerns of patients and clinicians. To test whether 
genetic risk was associated with disruptions to daily life, 
we analysed genetic associations with the incidence of 
days of school and work missed because of asthma, and 
with asthma-related hospital admissions. To put the 
magnitude of genetic risk eﬀ ects in context and to ﬁ nd 
out whether molecular genetic measurements provided 
novel information about risk, we compared molecular 
genetic information with family-history information.17 
Measures
A challenge for developmental research following up 
GWAS discoveries is that eﬀ ect sizes for individual 
asthma-associated single-nucleotide polymorphisms 
(SNPs) are small,9 meaning that longitudinal studies 
with the data necessary to investigate developmental 
phenotypes of asthma are underpowered to test 
individual SNP eﬀ ects.18 However, evidence shows that 
asthma-associated loci make additive contributions to 
risk, recommending aggregation of risk alleles.19,20 
Summing risk alleles across GWAS-identiﬁ ed SNPs to 
compute a genetic risk score yields a quantitative index 
of genetic risk with a normal distribution21 and a 
potentially larger eﬀ ect size. 
We derived our genetic risk score from the largest 
asthma GWAS to date, published in 2010.9 We selected 
all SNPs associated with asthma at p<5 × 10–⁸. This set of 
SNPs was then pruned using an R² threshold of 
0·60 to derive the SNP set for the genetic risk score. 
This process yielded 17 SNPs located in or near the genes 
IL18R1, IL13, HLA-DQ, IL33, SMAD3, ORMDL3, 
GSDMB, GSDMA, and IL2RB. 
Genotyping was done in the Dunedin Study cohort 
with a commercially available array (BeadPlex Array, 
Illumina, San Diego, CA, USA) using DNA extracted 
from whole blood (93%) or buccal swabs (7%). Two SNPs 
near the gene HLA-DQ could not be assayed because of 
the complex repetitive structure of the proximal 
sequence. Thus, the ﬁ nal genetic risk score included 
15 SNPs (appendix).
SNPs were genotyped in 880 (95%) of the 927 cohort 
members who reported European-descent grandparents. 
All SNPs met Hardy-Weinberg equilibrium criteria 
(p>0·10 for all tests). For each SNP, the risk allele was 
deﬁ ned as the asthma-associated allele in the original 
GWAS. Of a possible 30 risk alleles, cohort members 
carried a mean of 13·74 (SD 4·36). Risk allele counts were 
normally distributed (appendix). For analyses, we 
standardised the risk allele counts to have a mean of 0 and 
an SD of 1 (the genetic risk score). Eﬀ ect sizes presented 
are for a 1 SD change in genetic risk, which reﬂ ects the 
eﬀ ect associated with an increase of 4·36 risk alleles. Results 
of sensitivity analyses that selectively dropped SNPs from 
the score one by one showed that no single SNP accounted 
for a disproportionate share of the genetic-risk-score 
association with asthma (appendix). Cohort members’ sex 
and socioeconomic status were unrelated to their genetic 
risk (Pearson’s r=0·01 for sex and 0·04 for socioeconomic 
status).
See Online for appendix
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Family histories for asthma—ie, reports of asthma 
provided by study members and both parents for study 
members’ biological siblings, parents, and grandparents—
were available for 99% of the cohort. Family history was 
summarised as the proportion of family members in the 
pedigree who had asthma, adjusted for genetic relatedness 
to the proband (ie, ﬁ rst-degree relatives were counted as 
1 and second-degree relatives were counted as 0·5).22 
Assessments of asthma phenotypes and deﬁ nitions of 
biological variables including atopy, airway hyper-
responsiveness, and incompletely reversible airﬂ ow 
obstruction have been described in previous publications 
from this cohort10,23–33 and are summarised in table 1.
Statistical analysis
We analysed dichotomous outcomes (eg, asthma status) 
using Poisson regression models to derive relative risks 
(RRs). We analysed count phenotypes (eg, the number of 
assessments at which cohort members had current 
asthma) using negative binomial regression models to 
account for overdispersion. We report eﬀ ect sizes from 
negative binomial models in terms of incident rate ratios 
(IRRs). We analysed time to asthma onset using Cox 
regression models to derive hazard ratios (HRs). 
We analysed longitudinal repeated-measures data on the 
biological characteristics of asthma with generalised 
estimating equations to account for the non-independence 
of repeated observations.34 These analyses treated each 
assessment of a biological characteristic as an outcome, 
allowing us to diﬀ erentiate cases on the basis of 
persistence. All analyses were adjusted for sex and used 
the continuous genetic risk score (standardised to have a 
mean of 0 and a SD of 1). Eﬀ ect sizes are reported for a 
1 SD increase in genetic risk. 
Number of participants Assessment method
Developmental phenotypes of asthma
Asthma onset 305 (35%) of 
880 participants
Current asthma status was assessed at ages 9, 11, 13, 15, 18, 21, 26, 32, and 38 years from standardised interviews of study 
members (or their mothers if the participant was younger than 13 years) done by pulmonary specialists.10 Current asthma was 
deﬁ ned as a diagnosis of asthma in addition to positive symptoms within the past 12 months, including asthma attack, 
recurrent wheeze (excluding study members reporting only one or two episodes lasting less than 1 h), or medical treatment 
for asthma.23–25 Age at asthma onset was deﬁ ned as the earliest age at which wheezing symptoms or diagnosis by a physician 
were recorded
Life-course-persistent asthma 96 (11%) of 
880 participants
Asthma persistence was deﬁ ned by the number of assessments (out of nine) at which a cohort member had current asthma. 
Life-course-persistent asthma was deﬁ ned as having asthma at two or more assessments up to puberty (age 13 years) and at 
three or more assessments thereafter (ages 15–38 years)
Biological characteristics of asthma
Atopy 236 (77%) of 
305 participants with 
asthma 
Atopy was assessed once in childhood (at age 13 years) and twice in adulthood (at ages 21 and 32 years) by standardised skin 
tests26 for 12 common allergens: house dust mite (Dermatophagoides pteronyssinus), grass, cat, dog, horse, kapok, wool, 
Aspergillus fumigatus, Alternaria, Penicillium, Cladosporium, and cockroach (at ages 21 and 32 years only). A weal diameter 
2 mm greater than saline control was regarded as positive for epidemiological purposes. Atopy was deﬁned as a positive 
response to one or more allergens.27,28 Participants with asthma who tested positive for atopy were classiﬁ ed as having atopic 
asthma. In addition to allergy testing, total serum IgE, a blood biomarker of atopy, was measured once in childhood (at age 
11 years) and twice in adulthood (at ages 21 and 32 years).29 IgE values were log transformed for analysis
Airway hyper-responsiveness 160 (52%) of 
305 participants with 
asthma 
Airway hyper-responsiveness is an indirect measure of airway inﬂ ammation. During childhood (ages 9–13 years), and at ages 
15 and 21 years, spirometry and methacholine challenge was done using a Godart water spirometer. As described 
previously,28,30–32 a concentration of methacholine of 8 mg/mL or less causing a 20% decrease (PC20) in forced expiratory 
volume in 1 s (FEV₁) was used to identify airway hyper-responsiveness. In cohort members in whom a methacholine 
challenge was not safe or practical, an increase in FEV1 of 10% or more after albuterol was regarded as roughly equivalent to a 
PC20 of 8 mg/mL or less. This same method was used to deﬁ ne bronchodilator responsiveness at ages 18, 26, 32, and 
38 years. At these ages, spirometry was done with an Ohio computerised spirometer (Ohio Instruments, Cincinnati, OH, USA) 
at age 18 years, and a Sensormedics body plethysmograph (Sensormedics Corporation, Yorba Linda, CA, USA) at ages 26, 32, 
and 38 years. Asthma cases who met criteria for airway hyper-responsiveness to methacholine or albuterol were classiﬁ ed as 
having asthma with airway hyper-responsiveness
Incompletely reversible airﬂ ow 
obstruction
76 (25%) of 
305 participants with 
asthma 
Incompletely reversible airﬂ ow obstruction was deﬁ ned at ages 18, 26, 32, and 38 years as a post-bronchodilator ratio of FEV1 
to forced vital capacity (FVC) below the age-speciﬁ c and sex-speciﬁ c lower limits of normal.32 The lower limit of normal was 
deﬁ ned from cohort members with no previous history of asthma, no history of smoking, and no reported wheeze within 
the previous year as follows: the mean FEV₁-to-FVC ratio minus 1·96 SD, delimiting 2·5% of the normal population with the 
lowest post-bronchodilator FEV₁-to-FVC ratios.33 Participants with asthma who had incompletely reversible airﬂ ow 
obstruction by the end of follow-up were classiﬁ ed as having asthma with incompletely reversible airﬂ ow obstruction. We 
also analysed post-bronchodilator FEV₁-to-FVC ratio, a continuously distributed biomarker of incompletely reversible airﬂ ow 
obstruction
Asthma-related disruptions to daily life
Days of school or work missed 
because of asthma
158 (18%) of 
880 participants*
At ages 9, 11, 13, 15, 18, 21, 26, 32, and 38 years, cohort members (or their mothers if aged younger than 13 years) reported 
the number of days of missed school or work because of asthma
Admission to hospital for asthma 
or wheezing
72 (8%) of 880 participants At each assessment, cohort members (or their mothers if aged younger than 13 years) reported whether they had ever been 
admitted to hospital because of asthma or wheeze23
*Resulting in 2398 days oﬀ  school or work.
Table 1: Assessments of asthma phenotypes and deﬁ nitions of biological variables
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Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all of the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
Boys and girls in the Dunedin cohort who had higher 
genetic risk scores had a greater risk of developing 
asthma over the 38 years of follow-up than did those with 
lower genetic risk (HR 1·12, 95% CI 1·01–1·26), and 
developed asthma earlier in life (ﬁ gure 1). Genetic 
associations with asthma onset did not diﬀ er by 
sex (p=0·917).
Cohort members at higher genetic risk met criteria for 
current asthma at more assessments between the ages 
of 9 and 38 years than did those with lower genetic risk 
(IRR 1·16, 95% CI 1·03–1·30). Children at higher 
genetic risk were also more likely to develop life-course-
persistent asthma (96 [11%] of 880 participants), deﬁ ned 
by onset in childhood (before age 13 years) with recurrent 
Figure 1: Kaplan-Meier plots for development of asthma over time, by sex and genetic risk score
Kaplan-Meier plots show asthma onset in the whole Dunedin cohort according to sex (A) and high or low genetic risk score (B), and in girls only (C) and boys only (D) 
according to high or low genetic risk score. For illustrative purposes, high genetic risk was deﬁ ned as a genetic risk score above the cohort median. Numbers at risk are 
reported at ages 0, 7, 15, 21, 26, 32, and 38 years.
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symptoms up to age 38 years (RR 1·36, 95% CI 
1·14–1·63; ﬁ gure 2A). The shift in the genetic risk 
distribution that underlies this eﬀ ect is presented in the 
appendix. Speciﬁ cally, in the subset of cohort members 
with asthma onset in childhood (187 [21%] of 
880 participants), those at higher genetic risk developed 
asthma earlier in life than did those with lower genetic 
risk (HR 1·17, 95% CI 1·01–1·34) and were more likely 
to develop life-course-persistent asthma (RR 1·20, 
1·05–1·38; ﬁ gure 2B). Our receiver operating 
characteristic curve analysis showed that the genetic risk 
score slightly improves individual-level predictions of 
which participants with childhood-onset asthma 
developed life-course-persistent asthma (appendix). We 
did sensitivity analyses that restricted the life-course-
persistent subgroup to the 93 participants with asthma 
onset before the age of 9 years to test if results changed 
after exclusion of the three participants in the 
life-course-persistent group who developed asthma 
around the time of puberty. We noted that the results 
were unchanged (eﬀ ect sizes for genetic associations 
with life-course-persistent asthma were RR 1·37 [95% CI 
1·14–1·65] in the whole cohort and RR 1·20 [1·05–1·39] 
in participants who developed asthma in childhood). 
The results of our analyses in the 305 (35%) participants 
who developed asthma during follow-up showed that 
those at higher genetic risk were at increased risk of 
atopy compared with those with asthma and a lower 
genetic risk (RR 1·07, 95% CI 1·01–1·14) across 
assessments at age 13, 21, and 32 years. Participants with 
asthma at higher genetic risk also had raised serum IgE 
concentrations (r=0·13; p=0·02) across assessments at 
age 11, 21, and 32 years.
 Lung function analyses showed that participants with 
asthma at higher genetic risk were at increased risk of 
airway hyper-responsiveness to methacholine or albuterol 
relative to those with a lower genetic risk (RR 1·16, 
95% CI 1·03–1·32) across nine assessments between the 
ages of 9 and 38 years. These analyses also showed that 
participants with asthma at higher genetic risk had poorer 
lung function, as measured by a post-albuterol ratio of 
forced expiratory volume in 1 s (FEV₁) to forced vital 
capacity (FVC), than did those at lower genetic risk 
(r=0·13, p=0·03) and were more likely to develop 
incompletely reversible airﬂ ow obstruction, as deﬁ ned by 
post-bronchodilator FEV₁-to-FVC ratios of more than 
2 SD below the mean of participants who never developed 
asthma, than were those at lower genetic risk (RR 1·28, 
95% CI 1·04–1·57) across assessments at ages 18, 26, 32, 
and 38 years. Genetic associations with lifetime risk for 
atopy, airway hyper-responsiveness, and incompletely 
reversible airﬂ ow obstruction in participants with asthma 
are shown in the appendix.
Because smoking aﬀ ects the lung function charac-
teristics that we analysed,35 we did sensitivity analyses 
testing genetic associations with lung function phenotypes 
of asthma in non-smokers (ﬁ gure 3). By age 38 years, 
214 (70%) of the 305 cohort members with asthma had 
smoked at some point during follow-up (in the full cohort, 
627 [71%] of 880 had smoked). We previously constructed 
developmental phenotypes of smoking behaviour in the 
Dunedin cohort that identiﬁ ed when cohort members 
began smoking.36 We selectively excluded data from 
participants with asthma that were obtained after those 
individuals had begun smoking—eg, for a child who 
developed asthma at age 11 years and who took up 
Figure 2: Risk of developing life-course-persistent asthma according to genetic risk score 
(A) Whole cohort (relative risk [RR] 1·36, 95% CI 1·14–1·63). (B) Subset of cohort members with asthma onset by 
age 13 years (RR 1·20, 1·05–1·38). Error bars show 95% CIs for point estimates. The genetic risk score is the count of 
risk alleles standardised to have a mean of 0 and an SD of 1.
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asthma and all 305 participants with asthma. Probabilities were estimated from models including all participants 
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of risk alleles standardised to have a mean of 0 and an SD of 1.
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smoking at age 18 years, observations at ages 11, 13, and 
15 years were included in the analysis of airway 
hyper-responsiveness, whereas all observations from age 
18 years onwards were excluded. Participants who 
developed asthma after starting smoking were excluded 
from the analysis entirely. Excluding smokers increased 
the magnitudes of associations between genetic risk and 
airway hyper-responsiveness (RR 1·38, 95% CI 1·16–1·64) 
and incompletely reversible airﬂ ow obstruction (RR 1·63, 
1·10–2·41). 
Our results showed substantial overlap between atopy, 
airway hyper-responsiveness, and incompletely reversible 
airﬂ ow obstruction in participants with asthma. For 
example, 55 (72%) of 76 cohort members with asthma 
and incompletely reversible airﬂ ow obstruction also had 
atopy and airway hyper-responsiveness during follow-up 
(ﬁ gure 4A). Individuals with asthma who did not develop 
atopy had genetic risk scores similar to those without 
asthma. Of participants with asthma who developed 
atopy, those who also developed airway hyper-
responsiveness and incompletely reversible airﬂ ow 
obstruction had higher genetic risk scores than did those 
who had asthma and atopy only, and had the highest 
genetic risk scores of all participants (ﬁ gure 4B). 
Over three decades of follow-up, cohort members at 
higher genetic risk missed more days of school or work 
because of asthma than did those at lower genetic risk 
(IRR 1·38, 95% CI 1·02–1·86) and were more likely to be 
admitted to hospital for breathing problems (HR 1·38, 
1·07–1·79). 
Genotype and family history provided similar amounts 
of information about asthma risk; eﬀ ect sizes were 
similar for the genetic risk score and the family history 
score in models predicting developmental phenotypes of 
asthma, airway hyper-responsiveness, and asthma-related 
disruptions to daily life (table 2). Family history was not 
associated with risks of participants with asthma 
manifesting atopy or incompletely reversible airﬂ ow 
obstruction. 
Genotype-based and family-history-based measures 
provided diﬀ erent information about asthma risk. Cohort 
members’ genetic risk scores were unrelated to their 
family history scores (r=0·05; appendix). Adding statistical 
adjustments for family history to regression models 
testing genetic associations with asthma phenotypes and 
complications did not change the eﬀ ect size or statistical 
signiﬁ cance estimated for the genetic risk score. The one 
exception was that after adjustment for family history, the 
genetic association with incidence of days of school or 
work missed because of asthma was no longer statistically 
signiﬁ cant (IRR 1·32, 95% CI 0·98–1·79; p=0·07). 
Discussion
Results from our population-level analyses advance 
asthma genetics beyond the original GWAS discoveries 
in three ways. First, we show that genetic risks predict 
which individuals with childhood-onset asthma remit 
and which develop life-course-persistent asthma, 
although these predictions are not suﬃ  ciently sensitive 
or speciﬁ c to support immediate translation into clinical 
practice. Second, we elucidate a biological proﬁ le of 
asthma that arises from these genetic risks: atopic 
asthma characterised by airway hyper-responsiveness 
and leading to incompletely reversible airﬂ ow 
obstruction. Third, we describe the real-life eﬀ ects of 
GWAS discoveries by quantifying genetic associations 
with missed school and work, and hospital admissions. 
Cohort members at higher genetic risk developed 
asthma earlier in life, supporting GWAS reports of 
early-onset asthma as the developmental phenotype most 
strongly associated with discovered genetic risks 
(panel).9,37–39 We reﬁ ned this developmental phenotype by 
showing that discovered genetic risks were speciﬁ cally 
associated with a life-course-persistent developmental 
Asthma
Cohort members (n=880)
Asthma without atopy, AHR, or 
IRAO (n=49)
Asthma with atopy, without AHR 
or IRAO (n=79)
Asthma with atopy and AHR, 
without IRAO (n=89)
Asthma with atopy, AHR, and 
IRAO (n=55)
Asthma with AHR, without atopy 
or IRAO (n=12)
Asthma with atopy and IRAO, 
without AHR (n=13)
Asthma with AHR and IRAO, 
without atopy (n=4)
Asthma with IRAO without atopy 
or AHR (n=4)
Controls (n=575)
Atopy
AHR
IRAO
A
B
11 12 13 14 15 16
–0·6 –0·4 –0·2 0 0·2 0·4
Mean risk alleles carried
Genetic risk score
Asthma without atopy, AHR, or IRAO (n=49)
Asthma without atopy, with AHR and/or IRAO (n=20)
Asthma with atopy, without AHR or IRAO (n=79)
Asthma with atopy and AHR, without IRAO (n=89)
Asthma with atopy and IRAO, without AHR (n=13)
Asthma with atopy, AHR, and IRAO (n=55)
Figure 4: Atopy, airway hyper-responsiveness, and incompletely reversible airﬂ ow obstruction in participants 
with asthma 
(A) Overlap between diﬀ erent biological characteristics of asthma. (B) Mean genetic risk within subgroups of 
participants with asthma. Participants with asthma who did not have atopy but who did have airway 
hyper-responsiveness or incompletely reversible airﬂ ow obstruction are grouped together because of the small 
number of cases in each group. Error bars show SE for subgroup means. The genetic risk score is the count of 
risk alleles standardised to have a mean of 0 and a SD of 1. AHR=airway hyper-responsiveness. 
IRAO=incompletely reversible airﬂ ow obstruction.
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phenotype of asthma: of participants with childhood-onset 
asthma, those with a higher genetic risk were more likely 
to have persistent asthma up to age 38 years. Higher 
genetic risk asthma cases were also more likely to be 
atopic, supporting preliminary GWAS evidence that at 
least some asthma-associated loci are speciﬁ c to atopic 
asthma.40 We also show that in participants with asthma 
who also developed atopy, higher genetic risk predisposes 
these individuals to airway hyper-responsiveness and the 
development of incompletely reversible airﬂ ow 
obstruction. Collectively, these ﬁ ndings describe 
a biological proﬁ le of asthma associated with GWAS 
discoveries. Research is now needed to trace molecular 
pathways from these variants to atopy, airway 
hyper-responsiveness, and incompletely reversible 
airﬂ ow obstruction in asthma.
Genetic associations with developmental and biological 
characteristics of asthma translated to an increased 
burden of asthma-related disruptions to daily life. 
Participants with asthma at higher genetic risk missed 
more days of school and work over three decades of 
follow-up and were more likely to be admitted to hospital 
for asthma than were those with a lower genetic risk. 
Magnitudes of genetic eﬀ ects were small, with each SD 
increase in genetic risk score predicting an increase in 
risk for these disruptions to daily life by about a third. 
Nevertheless, results suggest that full mitigation of 
genetic risk could reduce the burden asthma imposes on 
patients, with potential beneﬁ ts accruing to society 
through reductions in school and work absenteeism, and 
in health-care costs. 
Finally, we tested whether recent GWAS discoveries 
captured information that might otherwise be obtained 
through a family history.41,42 GWAS discoveries for asthma 
provided novel information about inherited risk that was 
not captured by family history of asthma; the genetic risk 
score made independent, additive contributions to 
prediction models over and above family history. Both 
genotype-based and family-based risk measures predicted 
asthma onset and persistence, but genotype was a more 
consistent predictor of the biological characteristics of 
asthma. Surprisingly, genotypic risk was only weakly 
related to family history of asthma, with some cohort 
members with a negative family history carrying a high 
genetic risk for asthma. This lack of concordance between 
genotypic and family-based risk assessments is not 
unique to asthma. We previously noted this ﬁ nding in 
patients with obesity and smoking problems,36,43 and 
others have reported similar results for some patients 
with cancers.41 In studies of diabetes and cancer, taking 
family history into account did not change eﬀ ect sizes 
estimated for GWAS-discovered genetic risks,44,45 
suggesting low correlation between genotypic and 
family-history risk measures. In turn, this lack of 
correlation suggests that family history captures more 
than the additive contributions of common variants. 
Replication is needed of the non-association between 
 Statistic Genetic risk score Family history score
Developmental phenotypes of asthma (n=880)
Time to asthma onset HR 1·12 (1·01 to 1·26) 1·21 (1·10 to 1·34)
Asthma persistence IRR 1·16 (1·03 to 1·30) 1·24 (1·13 to 1·37)
Life-course-persistent asthma RR 1·36 (1·14 to 1·63) 1·33 (1·19 to 1·48)
Life-course-persistent asthma in participants 
with asthma onset by age 13 years (n=162) 
RR 1·20 (1·05 to 1·38) 1·09 (1·00 to 1·18)
Biological characteristics of asthma (n=305)*
Atopy
Positive skin test (at ages 13, 21, and 32 years) RR 1·07 (1·01 to 1·13) 1·03 (0·98 to 1·08)
Serum IgE (at ages 11, 21, and 32 years) r 0·13 (0·02 to 0·25) 0·10 (0·00 to 0·19)
Airway hyper-responsiveness 
Case status (at ages 9, 11, 13, 15, 18, 21, 26, 32, 
and 38 years)
RR 1·16 (1·03 to 1·32) 1·12 (1·05 to 1·21)
Incompletely reversible airﬂ ow obstruction
Case status (at ages 18, 26, 32, and 38 years) RR 1·28 (1·04 to 1·57) 1·05 (0·90 to 1·22)
Post-albuterol FEV1-to-FVC ratio (at ages 18, 
26, 32, and 38 years)
r –0·13 (–0·24 to –0·02) –0·07 (–0·16 to 0·02)
Disruptions to daily life (n=305)*
Days oﬀ  school or work because of asthma IRR 1·38 (1.02-1.86) 1·28 (1·02 to 1·61)
Admitted to hospital for asthma HR 1·38 (1·07 to 1·79) 1·21 (1·05 to 1·38)
Eﬀ ect sizes are presented for a 1 SD increase in genetic risk and a 1 SD increase in family history. Analyses of biological 
characteristics of asthma used generalised estimating equations to account for the non-independence of repeated 
observations of individuals. All models were adjusted for sex. HR=hazard ratio (Cox regression model). IRR=incident rate ratio 
(negative binomial regression model). RR=relative risk (Poisson regression model). r=standardised coeﬃ  cient (interpreted as 
Pearson’s r from a linear regression model). FEV1=forced expiratory volume in 1 s. FVC=forced vital capacity. *Analyses 
included only the 305 cohort members who developed asthma during follow-up.  
Table 2: Eﬀ ect sizes for genetic risk score and family history score 
Panel: Research in context
Systematic review
We searched databases, including PubMed and the National 
Human Genome Research Institute GWAS Catalog, to identify 
the largest and most comprehensive genome-wide association 
studies (GWAS) of asthma using the search terms “asthma” and 
“genome-wide association study”. We did not apply any 
publication date restrictions and did the last search on Sept 1, 
2012.  We identiﬁ ed a GWAS done by the European GABRIEL 
Consortium,9 from which we selected single nucleotide 
polymorphisms (SNPs) that were genome-wide signiﬁ cant 
(p<5×10–⁸) and that were at least partially independent of one 
another (R²<0·6) to construct a genetic risk score. 
Interpretation 
Our results, when added to those of the original GWAS,9 show 
that genetic risks predict which childhood-onset asthma 
cases remit and which become life-course-persistent cases, 
describe a biological proﬁ le of the asthma that arises from 
these genetic risks, and show the real-life eﬀ ects of GWAS 
discoveries by quantifying genetic associations with missed 
school and work, and hospital admissions. Because the eﬀ ect 
sizes we noted were small, the predictions oﬀ ered by genetic 
risk scores might be weak. More research is needed to clarify 
the clinical signiﬁ cance of the small increments in risk that 
can be predicted using SNPs.
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genetic risk and family history, using whole-genome 
scores.46 If replicated, future genetic discovery research in 
asthma could focus on genetic features of family history 
not detectable in GWAS, including rare variants, 
interactions among genes (epistasis) and, because family 
histories capture shared environments as well as genes, 
interactions between genes and environmental 
factors.8,47–49 Our ﬁ ndings also suggest that GWAS 
discoveries might help to identify which childhood-onset 
asthma cases are most likely to become life-course-
persistent cases, even after accounting for diﬀ erences in 
family histories of asthma. Because the eﬀ ect sizes we 
recorded were small, the predictions oﬀ ered by genetic 
risk scores might be weak. More work is needed to clarify 
the clinical signiﬁ cance of the small increments in risk 
that can be predicted using SNPs.50 
We acknowledge several limitations. First, our 
analyses were based on cohort members of European 
descent and for whom follow-up has extended only to 
age 38 years, limiting the extent to which we can 
generalise the results. Replication of ﬁ ndings in 
non-white cohorts and extension of ﬁ ndings beyond 
mid-life are crucial. Nevertheless, this birth cohort is 
one of the longest running with detailed clinical and 
objective measurements pertinent to asthma, and the 
cohort is representative of the population studied; it 
originated as an unselected birth cohort and has been 
followed up with a 95% retention. Second, because our 
study did not include medical records, some cases of 
asthma and hospital admission might have been missed 
or misclassiﬁ ed, leading to underestimation of genetic 
eﬀ ects. Third, our genetic risk score included only SNPs 
meeting genome-wide signiﬁ cance criteria in GWAS,9 
and omitted two of these because of technical limitations 
of the genotyping array. The genotyped SNPs represent 
only a subset of asthma-causing variants, many of which 
remain undiscovered.51 Further, because the relative 
eﬀ ect sizes of these SNPs on the developmental and 
biological characteristics of asthma that we analysed 
remain unknown, we did not weight the SNPs in our 
score. Whole-genome genetic risk score approaches that 
include hundreds or thousands of variants that meet 
more liberal signiﬁ cance criteria and that apply 
empirically deﬁ ned weighting schemes might yield 
more comprehensive measures of genetic risk.52 Such 
whole-genome scores are a work in progress in the case 
of asthma; eﬀ ect sizes reported in a recent whole-genome 
score study of asthma19 were similar to those in our 
study. Finally, because our genetic risk score approach 
studied the aggregate eﬀ ect of several asthma-associated 
SNPs, we cannot address the question of molecular 
mechanism. Larger samples and meta-analyses are 
needed to assess the speciﬁ c contributions of individual 
risk variants to developmental and biological 
characteristics of asthma. The contribution of our study 
is to guide such investigations by pointing to target 
phenotypes: early-onset, life-course-persistent asthma, 
and atopic asthma characterised by airway 
hyper-responsiveness and incompletely reversible 
airﬂ ow obstruction. 
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